复方苦参注射液对中晚期肝癌疗效meta分析  

A meta-analysis of compound kushen injection in the treatment for advanced hepatocellular carcinomas

作　　者：蒋雨薇[1,2] 杨波[1] 饶智国[1] 

机构地区：[1]广州军区武汉总医院肿瘤科 湖北中医药大学,武汉430070 [2]广州军区武汉总医院肿瘤科,武汉430070

出　　处：《中国医师杂志》2015年第6期803-806,共4页Journal of Chinese Physician

基　　金：湖北省自然科学基金资助项目（2011CDB017）

摘　　要：目的 系统评价复方苦参注射液（CKI）对中晚期肝癌的疗效和安全性.方法 计算机检索中文期刊全文数据库、中文科技期刊全文数据库、万方医学网和PubMed,检索时间至2014年11月,纳入单独常规支持治疗比较联合复方苦参注射液治疗中晚期肝癌的随机对照研究.根据Co-chrane协作网推荐的偏倚风险评估文献质量,采用Review Manager 5.3进行分析.以近期疗效、疼痛疗效有效率为效应指标.结果 纳入8篇RCTs共472例患者.Meta分析结果显示,治疗组近期疗效有效率更高（P=0.008）,治疗组肝癌患者疼痛缓解的有效人数高于对照组（P＜0.01）,未观察到明显不良反应.结论 复方苦参注射液对中晚期肝癌是一种有效的、安全的辅助药物。Objective To investigate the efficacy and safety of compound kushen injection （CKI）in the treatment for patients with advanced liver cancers.Methods Relevantly randomized controlled trials from China National Knowledge Infrastructure （CNKI）,Chinese Science and Technology Journal Database （VIP）,Wanfang Data,and Pubmed were searched until November,2014.Randomized controlled trials （RCTs） of supportive care compared with combined therapy of CKI in the treatment for patients with advanced liver cancers were included.The methodological quality of RCTs was assessed independently with bias risk according to the Cochrane collaboration.All data were analyzed with the Review Manager 5.3.Results Eight RCTs involving 472 patients were included.The meta-analysis results suggested that the shortterm efficacy of the treatment group be higher （P =0.008） and that the pain relief be a significant benefit in the treatment group （P 〈0.01）.Adverse reactions were not observed.Conclusions CKI is an effective and safe adjuvant drug for advanced liver cancers.

关 键 词：苦参/治疗应用 复方 注射剂 肝肿瘤/中药疗法 Meta分析 COMPOUNDS (TCD) 

分 类 号：R273[医药卫生—中西医结合]